Suppr超能文献

[非商业性临床试验——谁将成为合法申办者?依据德国药品法对研究者发起的临床试验的申办]

[Non-commercial clinical trials--who will be the legal sponsor? Sponsorship of investigator-initiated clinical trials according to the German Drug Law].

作者信息

Benninger-Döring G, Boos J

机构信息

Koordinierungszentrum für Klinische Studien, Universitätsklinikum Münster, 48129 Münster.

出版信息

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006 Jul;49(7):675-80. doi: 10.1007/s00103-006-1288-6.

Abstract

Non-commercial clinical trials may be of great benefit to the patients concerned. The 12th amendment to the German Drug Law (AMG) changed legal liability of the initiators of investigator-initiated clinical trials with extensive consequences for traditional project leaders. The central point under discussion is the sponsor's responsibility according to the AMG. Presently leading management divisions of university hospitals and universities are developing proceedings to assume sponsor responsibility by institutions (institutional sponsorship), which should enable investigator-initiated clinical trials to be conducted according to legal requirements in the future. Detailed problems and special questions can only be resolved in a single-minded fashion, and if necessary political processes should be catalyzed.

摘要

非商业性临床试验可能会给相关患者带来巨大益处。德国药品法(AMG)的第12次修订改变了研究者发起的临床试验发起者的法律责任,这对传统项目负责人产生了广泛影响。讨论的核心要点是AMG规定的申办者责任。目前,大学医院和大学的主要管理部门正在制定相关程序,以使机构承担申办者责任(机构申办),这有望在未来使研究者发起的临床试验能够依法开展。具体问题和特殊疑问只能通过一心一意的方式来解决,必要时还应推动政治进程。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验